Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Brief summary
The primary outcome of this study is the difference in the proportion of patients with a clinically relevant improvement in health status (≥0.4 improvement on the CCQ) between the triple therapy group and LABA/LAMA treatment groups at the end of the 26 weeks intervention period.
Interventions
DRUGFORMOTEROL AND ACLIDINIUM BROMIDE
DRUGFORMOTEROL AND GLYCOPYRRONIUM BROMIDE
DRUGFORMOTEROL
DRUGGLYCOPYRRONIUM BROMIDE AND BECLOMETASONE
DRUGOLODATEROL AND TIOTROPIUM BROMIDE
DRUGINDACATEROL AND GLYCOPYRRONIUM BROMIDE
Sponsors
General Practitioners Research Institute B.V.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study is the difference in the proportion of patients with a clinically relevant improvement in health status (≥0.4 improvement on the CCQ) between the triple therapy group and LABA/LAMA treatment groups at the end of the 26 weeks intervention period. | — |
Countries
Netherlands
Outcome results
None listed